94 reports

BIOTECH PHARMACEUTICAL BOEHRINGER- INGELHEIM inflammation, and autoimmunity (RIA); neuroscience; and gastrointestinal tract.

  • Breast Cancer
  • World
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • SAFETY OF HERCEPTIN MONOTHERAPY IN EARLY-STAGE HER2-POSITIVE BREAST CANCER
  • 9.4.7 XTANDI (ENZALUTAMIDE)

The MTD was not reached during this phase of the trial, and the majority of adverse events were mild or moderate gastrointestinal or hematological toxicities.

  • Breast Cancer
  • Forecast
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

CELLTRION CHUGAI PHARMACEUTICAL DAIICHI SANKYO DESCRIPTION Focusses on areas such as cardiovascular and metabolic disease (CVMD); oncology; respiratory, inflammation, and autoimmunity (RIA); neuroscience; and the gastrointestinal tract.

  • Breast Cancer
  • Amgen Inc.
  • Biocon Limited
  • Mylan Inc.
  • Roche Group

gastrointestinal segments.

  • Breast Cancer
  • World
  • AbbVie Inc.
  • AstraZeneca PLC
  • Roche Group
  • 5.2 ONCOLOGY TEST VOLUME
  • Rural China - Cancer Screening Sites by Cancer Type (Number), 2013
  • Breast Cancer
  • In Vitro Diagnostic Reagent
  • Asia
  • China
  • OriGene Technologies, Inc.

Other Relevant Information/ Insight Its brand portfolio enjoys an annual Product Portfolio: Radiology, Cardiology, Neurology, Urology, Orthopedics, Gastrointestinal and IT solutions growth rate of ##% since half a decade and has acquired almost ##. ##% share Allergens is continuously prov

  • Breast Cancer
  • Europe
  • North America
  • World
  • Market Size
  • Market drivers
  • Vendor landscape

However, these therapies are associated with considerable safety issues, such as gastrointestinal perforation, complications in wound healing, and hemorrhage in case of Avastin.

  • Breast Cancer
  • Alcon, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.

However, because the drug is associated with severe adverse reactions, it carries a boxed warning for gastrointestinal (GI) perforations, surgery, wound-healing complications, and hemorrhage.

  • Breast Cancer
  • Forecast
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • 9 Appendix

Treatment of exemestane with entinostat was well tolerated, and the most frequent AEs were fatigue, gastrointestinal disturbances and hematologic abnormalities.

  • Breast Cancer
  • Asia
  • World
  • Market Size
  • Novartis AG

The company produces and markets high-quality products and biologics in the areas of gastrointestinal disease, neurology, psychiatry, immunology, pain control, infectious disease, and oncology.

  • Breast Cancer
  • China
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • Beijing Novartis Pharma Ltd
  • 5.11 ATEZOLIZUMAB - ROCHE

Treatment of exemestane with entinostat was well tolerated, and the most frequent AEs were fatigue, gastrointestinal disturbances and hematologic abnormalities.

  • Breast Cancer
  • Asia
  • World
  • Novartis AG
  • Pfizer Inc.

Other symptoms include retrosternal pain, weight loss, hematemesis (vomiting blood) and melena (black feces associated with gastrointestinal hemorrhage).

  • Breast Cancer
  • World
  • Market Size
  • Celgene Corporation
  • Merck & Co., Inc.

Treatment of exemestane with entinostat was well tolerated and the most frequent AEs were fatigue, gastrointestinal disturbances and hematologic abnormalities.

  • Breast Cancer
  • World
  • Market Size
  • Novartis AG
  • Pfizer Inc.

The company produces and markets high-quality products and biologics in the areas of gastrointestinal disease, neurology, psychiatry, immunology, pain control, infectious disease, and oncology.

  • Breast Cancer
  • China
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group
  • Shenzhen Main Luck Pharmaceuticals Inc.

The double-balloon " push-pull" technique allows visualization and biopsy of the entire gastrointestinal tract.

  • Breast Cancer
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.

The double-balloon " push-pull" technique allows visualization and biopsy of the entire gastrointestinal tract.

  • Breast Cancer
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.

OTHER PRODUCTS ARE IN DEVELOPMENT IN RESPIRATORY CONDITIONS, BACTERIAL INFECTIONS, CNS/ PAIN, AND GASTROINTESTINAL DYSFUNCTION.

  • Breast Cancer
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

HOWEVER, BECAUSE THE DRUG IS ASSOCIATED WITH SEVERE ADVERSE REACTIONS, IT CARRIES A BOXED WARNING FOR GASTROINTESTINAL (GI) PERFORATIONS, SURGERY, WOUND-HEALING COMPLICATIONS, AND HEMORRHAGE.

  • Breast Cancer
  • Market Size
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

HOWEVER, BECAUSE THE DRUG IS ASSOCIATED WITH SEVERE ADVERSE REACTIONS, IT CARRIES A BOXED WARNING FOR GASTROINTESTINAL (GI) PERFORATIONS, SURGERY, WOUND-HEALING COMPLICATIONS, AND HEMORRHAGE.

  • Breast Cancer
  • World
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

HOWEVER, BECAUSE THE DRUG IS ASSOCIATED WITH SEVERE ADVERSE REACTIONS, IT CARRIES A BOXED WARNING FOR GASTROINTESTINAL (GI) PERFORATIONS, SURGERY, WOUND-HEALING COMPLICATIONS, AND HEMORRHAGE.

  • Breast Cancer
  • World
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

HOWEVER, BECAUSE THE DRUG IS ASSOCIATED WITH SEVERE ADVERSE REACTIONS, IT CARRIES A BOXED WARNING FOR GASTROINTESTINAL (GI) PERFORATIONS, SURGERY, WOUND-HEALING COMPLICATIONS, AND HEMORRHAGE.

  • Breast Cancer
  • World
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

GASTROINTESTINAL HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR TYPE ## (ALSO KNOWN AS ERBB## OR HER##/ NEU) ICD-## IARC JAPANESE COMPREHENSIVE CANCER NETWORK, BREAST JAPAN PHARMACEUTICAL MANUFACTURERS ASSOCIATION Kassenärztliche Bundesvereinigun KEY OPINION LEADER LOBULAR CARCINOMA IN SITU LUTEIN

  • Breast Cancer
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novartis AG
  • Pfizer Inc.

HOWEVER, BECAUSE THE DRUG IS ASSOCIATED WITH SEVERE ADVERSE REACTIONS, IT CARRIES A BOXED WARNING FOR GASTROINTESTINAL (GI) PERFORATIONS, SURGERY, WOUND-HEALING COMPLICATIONS, AND HEMORRHAGE.

  • Breast Cancer
  • Europe
  • Demand
  • Market Size
  • Novartis AG

PD-## BLOCKADE IN MISMATCH REPAIR DEFICIENT NON-COLORECTAL GASTROINTESTINAL CANCERS.

  • Breast Cancer
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Group

IN ADDITION, THE STUDY SHOWED THIS ADC HAS MANAGEABLE NEUTROPENIA AND GASTROINTESTINAL TOXICITIES.

  • Breast Cancer
  • United States
  • AbbVie Inc.
  • Roche Group
  • Seattle Genetics, Inc.
  • COMPANION DRUGS APPROVED BY FDA

IMATINIB, WHICH IS SOLD UNDER THE TRADE NAME GLEEVEC/ GLIVEC BY NOVARTIS, IS TARGETED AGAINST PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKAEMIA (PH+ CML), KIT (CD##)-POSITIVE GASTROINTESTINAL STROMAL TUMORS (GISTS) AND OTHER CANCERS.

  • Breast Cancer
  • World
  • Demand
  • Market Size
  • Roche Group

These instruments are intended for endoscopic gastrointestinal biopsy and should not be used for any purpose other than their intended function.

  • Biopsy
  • Breast Cancer
  • World
  • Forecast
  • Boston Scientific Corporation
  • Biotechnology
  • Breast Cancer
  • United States
  • Company Financials
  • Puma Biotechnology, Inc.

TSENG HAS PUBLISHED AND LECTURED INTERNATIONALLY ON THE DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL CANCER.

  • Biopsy
  • Breast Cancer
  • Clinical Trial
  • United States
  • GlobalData's company
  • Breast Cancer
  • Healthcare
  • Pharmaceutical
  • United States
  • Immunomedics, Inc.